Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Relevant literature concerning novel therapeutics for AD beyond targeted monoclonal antibodies antagonizing selectively interleukin (IL)-4 or IL-13 was obtained from a PubMed and clinicaltrials.gov search and summarized. 31622669 2020
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE The multifaceted roles of IL-4 and IL-13 in allergic disease development make IL-4Rα an attractive target for treatment strategies, and a neutralizing monoclonal antibody which antagonizes the effects of both IL-4 and IL-13 by blocking the interaction site found in the IL-4 receptor subunit α (IL-4Rα) has been successfully used to treat patients with moderate-to-severe AD. 31596502 2020
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE This review provides an update on the role of IL-13 in AD and discusses the different strategies aimed at interfering with its biologic activity as well as their potential in a precision medicine approach in the management of AD. 31230370 2020
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE The Th2 (IL-13) and Th22-related products (IL-22, S100A8/9/12) and serum IgE were significantly correlated with clinical severity (Scoring of Atopic Dermatitis [SCORAD]) in AA. 30223113 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Dupilumab, a fully human monoclonal antibody that binds IL-4Rα and inhibits signaling of both IL-4 and IL-13, has shown efficacy across multiple diseases with underlying type 2 signatures and is approved for treatment of asthma, atopic dermatitis and chronic sinusitis with nasal polyposis. 31838750 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Recently, cases of AA healing during treatment with anti-IL4/IL13 monoclonal antibody dupilumab (D) for AD were reported. 31306557 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Dupilumab, a monoclonal antibody blocking the action of IL-4 and IL-13 effectively reduces the symptoms of AD and itch. 31505056 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Tralokinumab treatment was associated with early and sustained improvements in AD symptoms and an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with AD. 29906525 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Decreased levels of IFN-γ (Th1) and IL-17 (Th17), IL-4 and IL-13 (Th2) were detected in T cells and the skin tissue from the MSC-Ex treated AD mice. 31036853 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE The overlap between the IL-13-stimulated epithelial cell transcriptome and the respective disease transcriptome was 22, 9, and 5% in EoE, AD, and AA, respectively, indicating a greater involvement of the IL-13 pathway in EoE than AA (<i>p</i> = 0.0007) or AD (<i>p</i> = 0.02). 31824894 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. 31066001 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. 30641038 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Notably, SCCAs are induced by IL-4 and IL-13, vital Th2 cytokines that play important roles in AD etiology. 31378660 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Among potential targets, interleukin 13 (IL-13) merits consideration, as monoclonal antibodies disrupting IL-13 signaling are proving to be exceedingly effective in common conditions such as atopic dermatitis. 30759882 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE In this study, we used keratinocytes and AD-like skin equivalent models using Th2 cytokines IL-4 and IL-13. 30506356 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Biologics targeting IL-13, such as the anti-IL-4Rα antibody dupilumab and the anti-IL-13 antibody tralokinumab, successfully improve AD lesions and further highlight the importance of IL-13 in the pathogenesis of AD. 31509236 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Although the presence of maternal atopic dermatitis (AD) was associated with increased gestational IL-13 concentrations [adj. 31428082 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 GeneticVariation disease GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Rare coding variants associated with AD are further enriched in 5 genes (IL-4 receptor [IL4R], IL13, Janus kinase 1 [JAK1], JAK2, and tyrosine kinase 2 [TYK2]) of the IL13 pathway, all of which are targets for novel systemic AD therapeutics. 31707051 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively). 30981576 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)-4 and IL-13] is approved for the treatment of patients with inadequately controlled, moderate-to-severe AD. 31407311 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE In acute lesions of AD, the T-helper type 2 cells produce interleukin (IL) 4, IL-13, and IL-31, which may potentiate barrier dysfunction and contribute to pruritus. 31690388 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis. 31123339 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Dupilumab, a monoclonal antibody that blocks the shared receptor subunit for interleukin (IL)-4 and IL-13, is currently approved for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD). 31424712 2019
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.200 Biomarker disease BEFREE Dupilumab, a fully human anti-interleukin 4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of Type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately-controlled moderate-to-severe atopic dermatitis in adults. 29193016 2018